Original news and analysis on international IP policy
Among the Ferraris, Maseratis and Lamborghinis in Geneva this week, high-level representatives of the auto industry, the UN International Telecommunication Union (ITU), the Fédération Internationale de l’Automobile (FIA) and the UN Economic Commission for Europe (UNECE) discussed issues of safety, data sharing and standardisation.
Incumbent Francis Gurry of Australia today was nominated to be the director general of the World Intellectual Property Organization until 2020, with WIPO members to make their final decision on 8 May. In his return to office, Gurry told reporters today he wants to focus on the digital marketplace, improving the organisation’s performance, changing geopolitics, and to steer journalists away from writing about allegations of wrongdoing at WIPO.
New business models for reducing markets for counterfeit and pirated goods were presented by speakers at the WIPO Advisory Committee on Enforcement this week, including voluntary mechanisms and graduated responses. But prices on brand name products was a little-explored issue during the presentations, only underlined as a possible factor of piracy by one developing country delegation.
A growing number of countries are signing the new World Intellectual Property Organization treaty on copyright exceptions aimed at boosting access to special format books for visually impaired persons. Parallel to the treaty and pre-dating it, a WIPO-led initiative of interested stakeholders is continuing its efforts to also boost access to such works, including through licence agreements.
The United Nations Conference on Trade and Development Working Group on Enhanced Cooperation held what was supposed to be its last meeting in Geneva on 24-28 February. However, as explained below, the group failed to agree certain key issues, so it agreed to meet again on 7-9 May. Richard Hill offers an explanation.
It began last May, when a tiny state in the United States launched a novel legal attack against a notorious patent troll. Other states and the federal government soon followed, all asserting that the troll’s efforts to licence its patents violated consumer protection laws. At first, this new legal strategy produced some significant victories. Many experts and government officials embraced consumer protection law as an important new tool against patent trolls. But a recent court ruling has cast doubt on the future of this once-promising strategy.
The intersection of biotechnology and intellectual property continues to be a hot topic across the globe. From the patenting of certain plant varieties to human genes, to biodiversity and food security, to genetic resources, countries from developing to developed are attempting to navigate often blurred lines in terms of what can and cannot be patented, what should - and shouldn’t - be patented, and protecting innovators from farmers to plant breeders to drug manufacturers.
Nazeem Mohamed is chief executive officer of Kampala Pharmaceutical Industries (KPI), a Ugandan generic manufacturer. Local manufacture of medicines is described by many, including the World Health Organization, as one of the tools that will increase access to medicines. Mohamed is former vice-president of strategic product development at Novo Nordisk, based in Belgium. He also worked for several leading multinational companies such as Pfizer and GlaxoSmithKline before his appointment as CEO of KPI.
With Intellectual Property Watch, Mohamed discussed KPI, the challenges of local drug production, the burden of non-communicable diseases, the issue of substandard medicines, rules engineered in the West which can hinder affordability and access in a least-developed country, unfair competition, and unmet skills building needs.
The much-debated Intellectual Property Laws Amendment Bill in South Africa, aimed at boosting protection for traditional knowledge, was signed by President Jacob Zuma without much fanfare and promotion. What happens now?
Over the last couple of years, news of pharmaceutical patents and India’s attempts to protect and manage its market has caught the attention of intellectual property observers everywhere and the pharmaceutical industry in particular.